Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Eatit digital program to help adults with obesity lose weight and improve eating habits

Official title: Eatit's Multimodal Digital Lifestyle Intervention for Obesity: A Clinical Pilot Study on Effects on Weight, Self-Rated Eating Habits and Self-Rated Health

Run by Eatit AB · NCT07183228 · Data updated 2026-11-12

This pilot will see if using Eatit's six-month, dietitian-supported digital lifestyle program helps adults with obesity lose weight, reduce waist size, and improve eating habits and self-rated health.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment93 (estimated)
SponsorEatit AB
Industry-sponsored
Locations1 site (Stockholm, Stockholm County)
StatusRecruiting
StartedSeptember 3, 2025
Main results expectedAugust 1, 2026
Study endsAugust 1, 2026
Registry record updatedSeptember 19, 2025
Trial IDNCT07183228 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with BMI ≥ 30 (or BMI 27–30 with specified comorbidity, prior obesity diagnosis, central obesity, or low Kostindex), who read Swedish, are not pregnant, and are not using or planning to start appetite-suppressing medication.

Probably not a fit

People who cannot engage with a digital program or video visits, those planning to use appetite-suppressing drugs, pregnant individuals, or patients with very complex needs that a dietitian judges require more intensive care may not benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label pilot enrolls about 93 adults with obesity who use Eatit's multimodal, dietitian-supported digital program for six months while serving as their own controls. Data are collected from Eatit's routine database and include weight, waist circumference, completed program modules and dietitian visits, plus self-reported Kostindex and WHODAS 2.0 (12-item) outcomes. Five study dietitians recruit participants through Eatit's normal patient flow and obtain consent during video assessment visits. The main outcome is change in body weight at six months, with secondary outcomes of waist size, eating habits, and self-rated health.

Why it matters

Potential benefit: If successful, the program could provide a more accessible and scalable option for weight loss and healthier eating for adults with obesity in Sweden.

How similar studies have gone: Previous digital, dietitian-supported lifestyle programs have produced modest but meaningful weight loss in some trials, though evidence from routine clinical practice is still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or older
* Body mass index (BMI) ≥ 30
* BMI 27-30 in combination with at least one of the following:

  1. Has received a diagnosis of obesity from another healthcare provider.
  2. Has a comorbidity (according to the defined diagnosis list under the heading Comorbidities below).
  3. Has central obesity, defined as waist circumference \> 80 cm for women or \> 94 cm for men.
  4. Kostindex score of 4 or lower - eligible for treatment due to increased risk of rapid future weight gain. Dietitian-led intervention may significantly impact weight development in this group.
* Ability to read and understand Swedish
* Does not currently use, and does not plan to initiate the use of, appetite-suppressing medication
* Not pregnant
* Patients with BMI \> 40, As long as there is no contraindication for treatment, treatment is offered. A dietitian may deny the patient the Eatit program if the dietitian assesses that the need for care is too great, and that Eatit's treatment cannot meet the patient's needs.

Comorbidities:

* Cardiovascular disease This is a large group of diagnoses, e.g. previous myocardial infarction or stroke, angina pectoris, heart failure, etc.
* Hypertension
* Elevated blood pressure, above 130/85 mmHg or ongoing treatment for previously diagnosed hypertension
* Hyperlipidemia
* Triglyceride levels ≥ 1.7 mmol/L or on treatment for elevated triglycerides, or LDL \> 3.0 mmol/L at low risk, or on treatment for high cholesterol, or reduced HDL-C \<40 mg/dL for men, \<50 mg/dL for women, or on treatment for HDL-C
* Obstructive sleep apnea
* Type 1 diabetes
* Type 2 diabetes
* Prediabetes (fasting glucose ≥ 6.1 or HbA1c \> 42 without a diabetes diagnosis)
* Fatty liver
* Polycystic ovary syndrome, PCOS
* Osteoarthritis in the lower body (e.g. hip, knee, or foot)

Exclusion Criteria:

* BMI: Patients with BMI \< 27 are excluded from treatment.
* Medical conditions: Patients with conditions where weight loss or weight gain may worsen the disease are excluded. For example: cancer or chronic obstructive pulmonary disease, COPD.
* Multimorbidity: Individuals with extensive comorbidities may have complex healthcare needs requiring more comprehensive medical support than Eatit can provide.
* Untreated depression may hinder participation in the program and should be managed with medical or psychological support.
* Untreated or ongoing eating disorder (bulimia nervosa, binge eating disorder, anorexia, atypical anorexia, ARFID) should be treated in a specialized eating disorder unit.
* Severe psychiatric illness (such as psychosis or schizophrenia) without ongoing support.
* Ongoing substance abuse (alcohol, narcotics, or medication) is a contraindication for participation and requires specialized addiction care.
* Suicidal behavior or self-harm in the past six months. Acute mental illness requires immediate and specialized interventions.
* Requires individual assessment. Certain conditions require individual evaluation as they may negatively affect treatment outcomes. This means that the treating dietitians should ask follow-up questions to ensure that participation in the program is feasible.
* Symptoms of binge eating not meeting criteria for binge eating disorder: Ensure that the person is willing to work with the program, not skip meals, and will inform you if the binge eating worsens.
* Depression under psychiatric care: Ask follow-up questions about what support the person is receiving and his or her current mental state.
* Bipolar disorder: Ask follow-up questions about what support the person is receiving and his or her current mental state.
* Exhaustion syndrome/stress: Ask follow-up questions to determine whether treatment is feasible at this time or if the patient needs to manage the stress in other ways first.
* Neuropsychiatric disorders: To benefit from the program, sufficient concentration ability and capacity for structure/planning in daily life are required. In case of a neuropsychiatric diagnosis, follow-up questions should be asked about whether the person believes that he or she can manage texts and tasks that take approximately 2-3 hours per week.
* High degree of psychiatric comorbidity has in some studies been shown to be a complicating factor, and this should also be considered at the start of treatment. Ask follow-up questions about what support the person is receiving and his or her current mental state.
* Severe sleep problems: Sleep deprivation may lead to increased appetite and reduced cognitive capacity, making it difficult to engage with treatment. Ask follow-up questions about possible undiagnosed sleep apnea or potential need for other care to address the sleep problems.

Where it's running

  • Eatit AB
    Stockholm, Stockholm County, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.